Correlations between genetically predicted lipid-lowering drug targets and inflammatory bowel disease
Abstract Background Millions of individuals globally suffer from Inflammatory bowel diseases (IBDs). There is a dearth of large population-based investigations on lipid metabolism and IBDs, and it is unclear whether lipid-lowering drugs target IBDs causally. Consequently, the aim of this study was t...
Main Authors: | Kuiyuan Huang, Shenan Huang, Ming Xiong |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-01-01
|
Series: | Lipids in Health and Disease |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12944-024-02026-y |
Similar Items
-
Lipids, lipid-lowering agents, and inflammatory bowel disease: a Mendelian randomization study
by: Heqing Tao, et al.
Published: (2023-06-01) -
Lipid-lowering drugs and inflammatory bowel disease’s risk: a drug-target Mendelian randomization study
by: Jiaxi Zhao, et al.
Published: (2024-01-01) -
Genetic evidence for the oral-gut axis between periodontitis and inflammatory bowel disease
by: Zhongyuan Wang, et al.
Published: (2023-10-01) -
Association of Antidiabetic Drug Target Genes with Inflammatory Bowel Disease: A Mendelian Randomization Study
by: Qing X, et al.
Published: (2024-02-01) -
Causal Effects of Blood Lipid Traits on Inflammatory Bowel Diseases: A Mendelian Randomization Study
by: Ziqin Yao, et al.
Published: (2023-06-01)